Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496950 | 1.00 | PSMB5 (0.47) | PSMB5SLC6A5PLA2G2APLA2G5ITGB3 | |
| SCHEMBL30496955 | 1.00 | PSMB5 (0.47) | PSMB5SLC6A5PLA2G2APLA2G5ITGB3 | |
| SCHEMBL29640331 | 1.00 | PSMB5 (0.47) | PSMB5SLC6A5PLA2G2APLA2G5ITGB3 | |
| SCHEMBL28520373 | 0.92 | PSMB5 (0.46) | PSMB5SLC6A5PLA2G2APLA2G5ITGB3 | |
| SCHEMBL19138237 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL9666470 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL19138225 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL15649757 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL20956613 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL4348856 | 0.91 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-4265629-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | Nissan Chemical Corporation (JP) | 2023-10-25 | — | — | EP | disclosed |
| CN-116648455-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-116615435-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | VIP, NGLY1, NPPA | PSMB5 3490/4885SLC6A5 1803/4885PLA2G2A 1062/4885 |
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NPPA, VIP, NGLY1 | PSMB5 2542/4885SLC6A5 1172/4885PLA2G2A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.